Completed PHASE2 INTERVENTIONAL 1-arm NCT00600353

Multi-day Doses in Prevention of Nausea and Emesis

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study

Sponsor: Eisai Inc.

Conditions Lymphoma, Malignant Myeloma, Plasma-Cell

Interventions Aprepitant Dexamethasone Palonosetron

Updated 7 times since 2017 Last updated: Jan 18, 2017 Started: Oct 31, 2007 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00600353, this PHASE2 trial focuses on Lymphoma, Malignant and Myeloma, Plasma-Cell and remains completed. Sponsored by Eisai Inc., it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.
University of Kansas Medical Center

Data source: University of Kansas Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kansas City, United States